Extracellular ATP and other purines play a crucial role in the vasculature, and their turnover is selectively governed by a network of ectoenzymes expressed both on endothelial and hematopoietic cells. By studying the whole pattern of purine metabolism in human serum, we revealed the existence of soluble enzymes capable of both inactivating and transphosphorylating circulating purines. Evidence for this was obtained by using independent assays, including chromatographic analyses with 3 H-labeled and unlabeled nucleotides and adenosine, direct transfer of γ-terminal phosphate from [γ-32 P]ATP to NDP/AMP, and bioluminescent measurement of ATP metabolism. Based on substrate-specificity and competitive studies, we identified three purine-inactivating enzymes in human serum, nucleotide pyrophosphatase (EC 3.6.1.9), 5′-nucleotidase (EC 3.1.3.5), and adenosine deaminase (EC 3.5.4.4), whereas an opposite ATP-generating pathway is represented by adenylate kinase (EC 2.7.4.3) and NDP kinase (EC 2.7.4.6). Comparative kinetic analysis revealed that the V max values for soluble nucleotide kinases significantly exceed those of counteracting nucleotidases, whereas the apparent K m values for serum enzymes were fairly comparable and varied within a range of 40-70 µmol/l. Identification of soluble enzymes contributing, along with membrane-bound ectoenzymes, to the active cycling between circulating ATP and other purines provides a novel insight into the regulatory mechanisms of purine homeostasis in the blood.
adenosine via ecto-5′-nucleotidase/CD73 reaction (6) (7) (8) . These two ecto-nucleotide hydrolases are ubiquitously coexpressed among the endothelial and hematopoietic cells and are considered to be the major regulators of the duration and magnitude of purinergic signaling in the blood (2, 9) . General schemes of nucleotide inactivation have also included a role for alkaline phosphatases, phosphodiesterases, and the members of the ecto-nucleotide pyrophosphatase (E-NPP) family, otherwise known as plasma cell membrane glycoprotein-1 (PC-1), autotaxin, B10 (10, 11) . The resulting adenosine interacts with its own G protein-coupled receptors (5) and usually serves as a powerful antiinflammatory agent with effects that are opposite of ATP/ADP (12) (13) (14) . Subsequently, the fate of adenosine is defined by its uptake into the cells via equilibrative or Na + -dependent nucleoside transporters (15) ; however, an alternative possibility of its extracellular deamination by ecto-adenosine deaminase anchored to the lymphocyte surface via CD26/dipeptidyl peptidase IV has been recently proposed (16, 17) . Along with purineinactivating pathways, backward nucleotide resynthesis via sequential ecto-nucleotide kinasemediated phosphotransfer reactions AMP → ADP → ATP has been described recently by us (8, 17) and others (18) (19) (20) .
In contrast to traditional paradigms that focus on cell-associated mechanisms of extracellular purine turnover, the existence of soluble enzymes in the blood and their contribution to the metabolism of circulating purines have received little attention. Although human plasma was shown to contain the major purine-degrading enzymes, including E-NPPs (21-23), E-NTPDases (24, 25) , adenosine deaminase (26) , alkaline phosphatases, and 5′-nucleotidase (27) , these enzymic activities were primarily considered in the context of their clinical applications as potential diagnostic tools in various (patho)physiological conditions. These studies aimed to evaluate the whole pattern of purine metabolism in human serum, and the results presented below demonstrate the existence of an extensive network of soluble enzymes coordinately mediating both degradation and transphosphorylation of circulating purines.
MATERIALS AND METHODS

Serum preparation
Blood was taken from healthy volunteers by venipuncture and was allowed to clot at room temperature for 30 min. Blood samples were centrifuged for 15 min at 2000g followed by freezing of the serum at -70°C. Serum was also obtained from White New Zealand rabbits and from FVB/n mice by collecting the blood from the heart immediately after the animals were killed.
Thin layer chromatography (TLC) analysis of the metabolism of 3 H-labeled nucleotides and adenosine
Nucleotide-converting activities were assayed with [2, H]ATP (specific activity 19 Ci/mmol; Sigma, St. Louis, MO), [2,8- 3 H]ADP (25.3 Ci/mmol; Sigma), and [2- H]AMP (18.6 Ci/mmol; Amersham, Little Chalfont, UK) as appropriate substrates. Serum (5-7 µl) was incubated at 37°C in a final volume of 60 µl RPMI-1640 medium containing 5 mmol/l β-glycerophosphate, the indicated concentrations of the substrate with tracer 3 H-nucleotide (∼4 × 10 5 dpm), and γ-phosphate-donating ATP/NTP (in case of nucleotide kinase studies). Incubation times were chosen to ensure the linearity of the reaction with time, so that the amount of the converted nucleotides did not exceed 15% of the initially introduced substrate. Aliquots of the mixture were applied to Alugram SIL G/UV 254 sheets (Macherey-Nagel, Duren, Germany) and separated by TLC with isobutanol/isoamyl alcohol/2-ethoxyethanol/ammonia/H 2 0 (9:6:18:9:15) (Fig. 1A) . 3 H-labeled substrates and their derivatives were visualized in UV light and quantified by scintillation β-counting, as described earlier (28) . Likewise, for measurement of adenosine deaminase, serum was incubated with [2- 3 H]adenosine (24 Ci/mmol; Amersham) followed by separation of 3 H-nucleosides with isobutanol/ethyl acetate/methanol/ammonia (7:4:3:4) (Fig.  1B) .
High-pressure liquid chromatography (HPLC) analysis of nucleotide metabolism
Serum (20 µl) was incubated for 30 min at 37°C with 50 µM NDP/NTP in the final volume of 300 µl RPMI-1640 medium followed by immediate extraction of exogenous nucleotides with 200µl of 0.6 mol/l perchloric acid. The obtained supernatant (450 µl) was neutralized with ~50 µl 4N KOH, clarified by centrifugation, and injected onto a 4-µm, 150 × 4.6 mm, Synergi Hydro-RP 80A column protected by reversed-phase C18 guard cartridges (all from Phenomenex, Torrance, CA). Buffer A was 0.1 mol/l KH 2 PO 4 (pH 6.0) supplemented with 1 mmol/l ion pairing reagent tetrabutylammonium dihydrogen phosphate (Fluka Chemica, Buchs, Switzerland), and buffer B was a 15% (v/v) solution of methanol in buffer A. The amount of buffer B was changed linearly between the following time points: 0 min, 0%; 1 min, 25%; 14 min, 35%; 18 min, 100%; 25 min, 100%; and 30 min, 0%. The reequilibration time was 10 min with buffer A, resulting in a total cycling time of 40 min between injections. The flow rate was 1 ml/min, and peaks were monitored by absorption at 258 nm. Individual standard curves were constructed with the use of known concentrations of nucleotide and nucleoside standards injected vs. the observed chromatographic peak areas (Fig. 1C) .
ATP quantification by luciferin-luciferase assay
Serum (15 µl) was incubated at room temperature in a final volume of 200 µl RPMI-1640 containing 1 mmol/l β-glycerophosphate and various NDP/NTP. Subsamples of the medium were mixed with EDTA at a final concentration of 2 mmol/l, and ATP concentration was assayed as described previously (29) . 
Data analysis
Pooled data are presented as mean ±SE, where n represents the number of experiments performed with separate serum samples in duplicates. Statistical comparisons were made using Student's t test, and P<0.05 were considered significant. Data from kinetic experiments were subjected to computer analyses, using the Michaelis-Menten equation to determine the K m and V max values (GraphPad Prism, version 3.03, San Diego, CA).
RESULTS
Catabolism of 3 H-labeled purines in human serum
In (Fig. 2B) . [ 3 H]ATP hydrolysis in the serum remained insensitive to inhibitors of ion-exchanging (ouabain) and intracellular (sodium azide, orthovanadate) ATPases but was partially inhibited by trypanocidal agent suramin concurrently serving as antagonist of P2 receptors and inhibitor of E-type ATPases (Fig. 2B ). Serum was also capable of hydrolyzing [ 3 H]AMP, and this nucleotidase reaction can be prevented with the specific ecto-5′-nucleotidase inhibitor α,β-methylene-ADP (APCP) but not with suramin ( Fig.  2C ). Together, these findings suggest the presence of at least two nucleotide-hydrolyzing activities in human serum that display strong cation dependence, coordinately degrade ATP via AMP to adenosine, and are differently modulated by inhibitors.
Although adenosine was the principle metabolite formed in the course of [ 3 H]ATP hydrolysis, slight generation of 3 H-labeled inosine and hypoxanthine suggests the presence of other soluble purine-inactivating enzymes, adenosine deaminase and probably purine nucleoside phosphorylase, in human serum ( Fig. 2A) . For direct quantification of adenosine deaminase activity, we used [ 3 H]adenosine as initial substrate and particular solvent mixture that enabled better TLC separation of 3 H-labeled adenosine and its nucleoside metabolites (see Materials and Methods and Fig. 1 ). Indeed, human serum successfully deaminates [ 3 H]adenosine, and this catalytic reaction was inhibited by ∼95% in the presence of adenosine deaminase inhibitor EHNA (Fig. 2C) .
Transphosphorylation of 3 H-labeled and unlabeled nucleotides in human serum
To test the alternative possibility of backward ATP resynthesis in cell-free serum, we determined the conversion of 3 H-labeled AMP/ADP into high-energy
Kinetic analysis of soluble purine-converting enzymes
In the context of a complex mixture of enzymes sharing similarities in substrate specificity, the role of individual components primarily depends on the enzyme kinetics and local substrate concentrations. (Fig. 4B ). All enzyme assays were conducted under the same initial rate conditions, and the kinetic parameters were calculated using the Michaelis-Menten equation. Except for adenylate kinase with relatively low substrate affinity, the apparent K m values for other serum enzymes, 5′-nucleotidase, adenosine deaminase, NDP kinase (Fig. 4C) , and ATPase (30) , are fairly comparable and vary within a range of 40-70 µmol/l. However, the V max values for adenylate kinase and especially NDP kinase significantly exceed those of purine-inactivating enzymes (Fig. 4C) , suggesting the predominance of phosphotransfer reactions under simultaneous appearance of ATP and NDP/AMP in the external milieu.
HPLC analysis of nucleotide metabolism in human serum
Nucleotide-converting activities were also evaluated by using HPLC. Nucleotides and nucleosides were identified by construction of the individual standard curves (see Fig. 1C ) as well as by internal injections of authentic standards. The major peak corresponding to hypoxanthine was clearly detected in the case of control nontreated serum (Fig. 5A ), and these findings are consistent with earlier established "hypoxanthine pool" freely circulating in human blood (31) . Addition of exogenous ADP to the serum caused its simultaneous conversion into AMP and ATP presumably via reverse adenylate kinase reaction (Fig. 5B) , whereas GTP alone did not induce significant shifts in serum purine metabolism (Fig. 5C ). Combined serum treatment with ADP plus GTP dramatically activated NDP kinase-mediated phosphotransfer reactions through the following scheme: ADP + GTP ↔ ATP + GDP (Fig. 5D ).
Bioluminescent determination of ATP metabolism in human serum
Phosphotransfer reactions in human serum were independently measured by using a luciferinluciferase assay. Serum incubation with 4.5 µmol/l ADP caused detectable ATP formation ( Fig.  6A; inset) , and these data fit well with the above radio-TLC measurements of [ 3 H]ADP phosphorylation into [ 3 H]ATP (see Fig. 3B ; first bar) and with HPLC analysis of ADP metabolism (see Fig. 5B ). Together, these findings can be reasonably explained by reverse soluble adenylate kinase reaction mediating transphosphorylation of two ADP molecules into ATP and AMP. However, the most pronounced ATP synthesis was observed under combined serum exposure to ADP and various NTP (Fig. 6A) confirming the necessity of a γ-phosphatedonating NTP for efficient ADP conversion into ATP via soluble NDP kinase reaction. Vice versa, serum incubation with ATP alone induced its modest hydrolysis, whereas UDP, IDP, and to a lesser extent, GDP accelerated ATP metabolism via activation of phosphotransfer reactions (Fig. 6B) .
Serum was incubated with [γ-
32 P]ATP, and Figure 7 illustrates the major interconversion pathways of this nucleotide. Incubation of human serum with 1-50 µmol/l [γ- 32 32 PP i (lane 7), which may be reasonably explained by the ability of NPPs to metabolize diadenosine polyphosphates as an alternative substrates (11).
Assessment of reliability of the used approaches
Studies on purine metabolism in serum or plasma must be performed and interpreted with certain caution because even slight hemolysis during blood sampling would induce the appearance of artificially high levels of ATP and other nucleotides. However, concentration of ATP in the analyzed serum samples was <10 −8 mol/l as measured by highly sensitive luciferin-luciferase assay. In addition, HPLC analysis did not reveal any traces of other NTP/NDP even at the highest sensitivity range (detection limit ∼5-10 pmol per injection). Use of a large excess of β-glycerophosphate as an alternative phosphorylated substrate in all enzyme assays also allowed us to exclude the potential contribution of nonspecific phosphatases in the measured activities. Furthermore, additional ultracentrifugation of the serum (60 min at 100,000g) did not significantly affect the activities of soluble enzymes, thus excluding the possible contribution of membrane-bound ectoenzymes that could be associated with fine cell fragments and not precipitated during routine preparation of the blood samples.
DISCUSSION
By using radio-TLC and HPLC assays as the most sensitive and versatile approaches for screening the metabolism of extracellular purines, we evaluated the whole pattern of purine metabolism in human serum and further identified the major soluble activities involved in these interconversion pathways. The elements of the purine-inactivating cascade comprise at least three separate enzymes displaying ATP-pyrophosphohydrolyzing, AMP-hydrolyzing, and adenosine-deaminating activities, whereas an opposite ATP-regenerating pathway is mediated via sequential adenylate kinase and NDP kinase reactions (Fig. 8 ).
An unambiguous distinction between the members of the E-NTPDase and the E-NPP family is complicated by their coexpression to a variable extent among the mammalian tissues, sharing similarities in substrate specificity (10, 11) , similar pattern of inhibition by some P2 antagonists such as suramin and pyridoxalphosphate azophenyl disulphonic acid (PPADS), and insensitivity to the classic inhibitors of intracellular ATPases (32) (33) (34) . The E-NPPs are particularly abundant in fibroblasts, chondrocytes, and osteoblasts, where they regulate soft tissue calcification and bone mineralization (35) , whereas E-NTPDases dominate in the vascular endothelium and are usually considered to be the major regulators of blood fluidity and platelet activation (2, 4) . Soluble NPPs can also be liberated via proteolysis of the parent membrane-bound molecules and are primarily represented in plasma by 127-kDa isozyme NPP1 (otherwise known as PC-1) (35, 36) . Serum PC-1 levels have been shown to be elevated in patients with degenerative arthritis and scleroderma (23) and decreased in idiopathic infantile arterial calcification (21). Soluble ATP-hydrolyzing activities have also been described in human plasma (24, 25, 30) .
Present TLC studies with [γ-32 P]ATP as substrate clearly demonstrate that practically all ATP in human (and rabbit) serum is directly converted into AMP, presumably via NPP1/PC-1-mediated pyrophosphatase reaction. The patterns of ATP hydrolysis in mouse (see Fig. 7 ) and rat (30) serum samples suggest the existence of other nucleotidases in rodent blood. These enzymes may include other members of the NPP family such as NPP2/autotaxin, which can also be secreted to the bloodstream, sequentially hydrolyze both ATP and ADP, and is even capable of cleaving PP i to two P i (11, 35) . Alternatively, we do not exclude the coexistence of two independent, NPPlike and NTPDase-like, activities in mouse serum. Furthermore, recent data on the secretion of soluble E-NTPDases from the nerve terminals (37) and from vascular endothelial cells (29) suggest the possibility of transient appearance of soluble NTPDases in human blood under certain (patho)physiological conditions and their contribution to local metabolism of extracellular ATP.
Circulating AMP can be degraded to adenosine and further to inosine by serum 5′-nucleotidase and adenosine deaminase, respectively. The 5′-nucleotidase/CD73 is an ubiquitously expressed ectoenzyme attached to the membrane matrix via GPI anchor (6, 38) and, under various stimuli, it can be released into external milieu from nerve terminals (37), endothelial cells (29) , and lymphocytes (39) . The major source of soluble 5′-nucleotidase in the blood is thought to be the plasma membranes of hepatocytes, and serum 5′-nucleotidase is increased in certain hepatobiliary, hematological, immunological, and neoplastic disorders (27) . Another purineinactivating enzyme, adenosine deaminase, is widely expressed in intestine, thymus, and other lymphoid and nonlymphoid tissues (13, 40) . Serum also contains soluble adenosine deaminase that seems to originate from lymphocytes or the monocyte/macrophage lineage, and its activity is changed in various diseases in which the immune status is changed, such as rheumatoid arthritis and tuberculosis (26) . Although the existence of purine-converting enzymes has been described earlier in human plasma, here for the first time we performed comparative and kinetic analyses of these soluble enzymes.
Understanding the impact of serum enzymes on the purine homeostasis within the larger framework of membrane-associated ecto-nucleotidases is another important issue. Endothelial ENTPDases, in concert with ecto-5′-nucleotidase, are thought to be the major terminators of the proinflammatory and prothrombotic effects of ATP/ADP in the vasculature (9) . However, endothelial metabolism prevails in the microcirculation, where the area of endothelial surface exposed to unit volume of blood is very high, whereas within large vessels, the capacity to metabolize circulating purines resides approximately equally at the luminal surface of the vessel wall and in the flowing blood (24) . Soluble nucleotidases can also potentially offset the reduced scavenging effectiveness of membrane-bound ecto-nucleotidases under certain inflammatory conditions or traumatic shock where the integrity of a blood vessel wall is compromised. In this context, it is pertinent to note that the recombinant soluble form of human NTPDase/CD39 was capable of potently inhibiting thrombosis and tissue injury even when given to mice 3 h after stroke (41) , and it is currently considered a promising aspirin-insensitive antithrombotic drug (2, 4) . Importantly, contrary to the endothelial and lymphocyte E-NTPDases, serum NPPs directly convert ATP into AMP and PPi, thereby bypassing the generation of a principal plateletrecruiting agent ADP. In addition, because PPi is one of the major physiological inhibitors of calcification, preventing basic calcium phosphate (hydroxyapatite) crystal deposition in bone and cartilage (35) , serum NPPs may concurrently serve as powerful physiological inhibitors of mineralization in vivo.
Another important novelty of this work is the demonstration of the hitherto unrecognized ATPgenerating pathway in human serum that is sequentially mediated via phosphotransfer reactions. Although both adenylate kinase and NDP kinase have been traditionally viewed as intracellular regulators of endogenous nucleotide pools, recent studies demonstrated the expression of these ectoenzymes on the surface of endothelial cells (8, 19) , lymphocytes (17) , and other cell types (18, 20) . Interestingly, a certain proportion of ecto-nucleotide kinases can be secreted from airway submucosal glands in response to cholinergic stimuli (20) . The identification of soluble NDP kinase capable of rapidly (within minutes) and indifferently transphosphorylating micromolar concentrations of nucleoside di-and triphosphates may represent an auxiliary and currently unappreciated route regulating the pattern of nucleotide receptor stimulation and/or desensitization in the blood. Particularly, in the settings of thrombus formation, where ADP and other nucleotides are massively released from dense granules of activated platelets and injured endothelium (2, 4) , rapid interconversion of ADP/NTP by serum NDP kinase could prevent recruitment of additional platelets via a directional switch between purine-and pyrimidineselective receptors. Serum adenylate kinase may also contribute to the clearance of circulating ADP through its reverse transphosphorylation into ATP and AMP.
In conclusion, the results presented here demonstrate the coexistence of two opposite, ATPgenerating and ATP-consuming, pathways in cell-free human serum, and these findings may significantly add to our understanding of the regulation of the duration and magnitude of purinergic signaling in the blood. In addition, there is increasing interest in the therapeutic potential of purinergic compounds, and these strategies are likely to include search for selective agonists and antagonists for P1 and P2 receptor subtypes (42) , regulation of extracellular purine metabolism by using antiinflammatory drugs (14) , and enzyme therapies with recombinant soluble E-NTPDases (4, 41) . Therefore, our findings may open up further research to assess the potential diagnostic applications of purine-converting enzymes in clinical biochemistry. 
